399 related articles for article (PubMed ID: 20809203)
1. Bone loss in diabetes: use of antidiabetic thiazolidinediones and secondary osteoporosis.
Lecka-Czernik B
Curr Osteoporos Rep; 2010 Dec; 8(4):178-84. PubMed ID: 20809203
[TBL] [Abstract][Full Text] [Related]
2. Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.
Schwartz AV; Sellmeyer DE
Expert Opin Drug Saf; 2008 Jan; 7(1):69-78. PubMed ID: 18171315
[TBL] [Abstract][Full Text] [Related]
3. Skeletal consequences of thiazolidinedione therapy.
Grey A
Osteoporos Int; 2008 Feb; 19(2):129-37. PubMed ID: 17901911
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
Grey A
Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
[TBL] [Abstract][Full Text] [Related]
5. [Do thiazolidinediones harm skeletal integrity?].
Takeuchi Y
Clin Calcium; 2008 May; 18(5):650-5. PubMed ID: 18445884
[TBL] [Abstract][Full Text] [Related]
6. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.
Orasanu G; Ziouzenkova O; Devchand PR; Nehra V; Hamdy O; Horton ES; Plutzky J
J Am Coll Cardiol; 2008 Sep; 52(10):869-81. PubMed ID: 18755353
[TBL] [Abstract][Full Text] [Related]
7. The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
Beck GR; Khazai NB; Bouloux GF; Camalier CE; Lin Y; Garneys LM; Siqueira J; Peng L; Pasquel F; Umpierrez D; Smiley D; Umpierrez GE
Transl Res; 2013 Mar; 161(3):145-55. PubMed ID: 23022285
[TBL] [Abstract][Full Text] [Related]
8. Bone as a target of type 2 diabetes treatment.
Lecka-Czernik B
Curr Opin Investig Drugs; 2009 Oct; 10(10):1085-90. PubMed ID: 19777397
[TBL] [Abstract][Full Text] [Related]
9. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
10. The safety of thiazolidinediones.
Tolman KG
Expert Opin Drug Saf; 2011 May; 10(3):419-28. PubMed ID: 21366501
[TBL] [Abstract][Full Text] [Related]
11. Thiazolidinedione use and bone loss in older diabetic adults.
Schwartz AV; Sellmeyer DE; Vittinghoff E; Palermo L; Lecka-Czernik B; Feingold KR; Strotmeyer ES; Resnick HE; Carbone L; Beamer BA; Park SW; Lane NE; Harris TB; Cummings SR
J Clin Endocrinol Metab; 2006 Sep; 91(9):3349-54. PubMed ID: 16608888
[TBL] [Abstract][Full Text] [Related]
12. Thiazolidinediones: a review of their mechanisms of insulin sensitization, therapeutic potential, clinical efficacy, and tolerability.
Vasudevan AR; Balasubramanyam A
Diabetes Technol Ther; 2004 Dec; 6(6):850-63. PubMed ID: 15684639
[TBL] [Abstract][Full Text] [Related]
13. Rational drug design and PPAR agonists.
Perfetti R; D'Amico E
Curr Diab Rep; 2005 Oct; 5(5):340-5. PubMed ID: 16188168
[TBL] [Abstract][Full Text] [Related]
14. The current role of thiazolidinediones in diabetes management.
Rizos CV; Kei A; Elisaf MS
Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
[TBL] [Abstract][Full Text] [Related]
15. Thiazolidinediones: effects on insulin resistance and the cardiovascular system.
Quinn CE; Hamilton PK; Lockhart CJ; McVeigh GE
Br J Pharmacol; 2008 Feb; 153(4):636-45. PubMed ID: 17906687
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
17. PPAR- γ agonist in treatment of diabetes: cardiovascular safety considerations.
Abbas A; Blandon J; Rude J; Elfar A; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2012 Jun; 10(2):124-34. PubMed ID: 22471957
[TBL] [Abstract][Full Text] [Related]
18. Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?
Mannucci E; Monami M
Curr Diab Rep; 2009 Oct; 9(5):342-7. PubMed ID: 19793503
[TBL] [Abstract][Full Text] [Related]
19. PPARgamma agonists and coronary atherosclerosis.
Sulistio MS; Zion A; Thukral N; Chilton R
Curr Atheroscler Rep; 2008 Apr; 10(2):134-41. PubMed ID: 18417068
[TBL] [Abstract][Full Text] [Related]
20. Association of thiazolidinediones with gastric cancer in type 2 diabetes mellitus: a population-based case-control study.
Chang SS; Hu HY
BMC Cancer; 2013 Sep; 13():420. PubMed ID: 24041200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
